Collegium Pharmaceutical Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Other analysts have also recently issued research reports about the company. Jefferies Group reissued a “buy” rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Gabelli assumed coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target for the company. Finally, Piper Jaffray Cos. set a $23.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up 3.00% during trading on Wednesday, reaching $18.19. The company’s stock had a trading volume of 378,623 shares. The company has a 50 day moving average of $13.10 and a 200-day moving average of $14.51. Collegium Pharmaceutical has a 12-month low of $8.24 and a 12-month high of $30.58. The stock’s market cap is $427.97 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. Analysts forecast that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In related news, Director John A. Fallon acquired 2,375 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 12th. The stock was acquired at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the purchase, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 37.93% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in COLL. Royal Bank of Canada raised its position in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in Collegium Pharmaceutical during the second quarter worth $253,000. Highbridge Capital Management LLC bought a new position in Collegium Pharmaceutical during the second quarter worth $166,000. Sabby Management LLC raised its position in Collegium Pharmaceutical by 23.5% in the second quarter. Sabby Management LLC now owns 101,410 shares of the specialty pharmaceutical company’s stock worth $1,202,000 after buying an additional 19,310 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Collegium Pharmaceutical during the second quarter worth $148,000. Institutional investors and hedge funds own 62.13% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.